OR2AT4

Across TCGA pan-cancer cohorts, OR2AT4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR2AT4 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR2AT4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR2AT4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, ESCA, and LIHC are the cancer types where OR2AT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.912	0.597	.007	19	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LGG	OS	Median	All	0.295	0.811	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR2AT4–SKCM (DFS)

Open the SKCM breakdown →